Safety, Tolerability, and Pharmacokinetics Phase ⅠStudy of a Selective 5-ht6 Receptor Antagonist, HEC30654AcOH, Following Single and Multiple Ascending Doses Single-center, Randomized, Double-blind in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Apr 2019
Price : $35 *
At a glance
- Drugs HEC30654-AcOH (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Sunshine Lake Pharma
- 02 Apr 2019 Planned End Date changed from 23 Apr 2019 to 30 Nov 2019.
- 02 Apr 2019 Planned primary completion date changed from 23 Feb 2018 to 30 Oct 2019.
- 28 Nov 2018 Planned End Date changed from 23 Jan 2019 to 23 Apr 2019.